We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Molecular Assay Detects Norovirus in Fecal Specimens

By LabMedica International staff writers
Posted on 09 Jan 2014
A new real-time reverse transcription polymerase chain reaction (RT-PCR) assay has been evaluated in for the detection of human Norovirus in stool specimens.

Noroviruses are a genetically diverse group of single-stranded ribonucleic acid (RNA), nonenveloped viruses in the Caliciviridae family and are classified into five genogroups by phylogenetic analysis of the capsid protein, of which genogroups II (GII), I (GI), and IV (GIV) are responsible for human outbreak. More...


Scientists at the Hallym University College of Medicine (Seoul, South Korea) analyzed 281 fecal suspensions (10% to 20% fecal specimen diluted with saline) collected and stored at -70 °C between August 2010 and April 2011. These comprised 109 Norovirus-positive and 172 Norovirus-negative stool samples, as determined using a Norovirus enzyme-linked immunosorbent assay (ELISA).

RNA was extracted from fecal suspensions and prepared using the QIAamp Viral RNA Mini Kit (Qiagen; Hilden, Germany) and the Qiagen QIAcube platform. The AccuPower Norovirus Real-time RT-PCR assay (Bioneer Corporation; Daejeon, South Korea) and the RIDAGENE Norovirus V assay (R-Biopharm, Darmstadt, Germany) were compared as Norovirus assays. Norovirus positivity and genotype were confirmed by direct sequencing.

Of the 109 Norovirus-positive samples by ELISA, 91 (83.5%) were positive by both PCR kits, and two (1.8%) were positive only by the AccuPower kit, whereas 16 cases (14.7%) were negative by both PCR kits. Of the 172 Norovirus-negative samples by ELISA, 159 (92.4%) were negative, and five (2.9%) were positive by both PCR kits, one (0.6%) was positive by the RIDAGENE kit, and seven (4.1%) were positive by the AccuPower kit. The lowest mean numbers of genome copies of GI and GII that could be detected by the AccuPower assay were 12.3 and 5.6 RNA copies/reaction, respectively.

The authors concluded that the AccuPower Norovirus Real-time RT-PCR Kit showed good analytical and clinical performance, including excellent analytical sensitivity and reproducibility, without cross-reactivity and they recommend this assay system as an efficient diagnostic tool for Norovirus infection. Noroviruses are responsible for an estimated 218,000 deaths each year among children younger than five years in developing countries and 1.1 million hospitalizations worldwide. The study was published in the January 2014 edition of the journal Diagnostic Microbiology and Infectious Disease.

Related Links:

Hallym University College of Medicine
Qiagen
Bioneer Corporation 




Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Turbidimetric Control
D-Dimer Turbidimetric Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.